Provided that the recently developed SOCS1/3 antagonist has a potent antiviral function against a broad group of viruses, such as herpes simplex virus-1, vaccinia virus, and influenza virus [50,51], it will be interesting to evaluate the effect of these antagonists against ZIKV infection. Here, SOCS1 is linked to Zika virus infectious disease.